Intermittent Fasting and GLP 1 for Reduce Inflammation: A Powerful Combination for Weight Loss and Improved Health
In recent years, intermittent fasting (IF) has gained popularity as a way to lose weight, improve insulin sensitivity, and reduce inflammation. Meanwhile, glucagon-like peptide 1 (GLP-1) receptor agonists have become a commonly prescribed medication for type 2 diabetes and weight management. What if you could combine the benefits of IF and GLP-1 to create a powerful synergy that amplifies weight loss and improves overall health?
What is GLP-1 and How Does it Work?
GLP-1, also known as glucagon-like peptide 1, is a hormone produced by the intestines in response to food intake. It plays a crucial role in glucose metabolism, appetite regulation, and insulin sensitivity. GLP-1 receptor agonists, such as semaglutide and tirzepatide, mimic the action of natural GLP-1, promoting weight loss, improving glycemic control, and reducing inflammation.
The Conceptual Model of Synergy
Figure 1 illustrates the conceptual model of synergy between IF and GLP-1. This model highlights how GLP-1 initiation reduces hunger and facilitates IF, which in turn fosters lifestyle empowerment, decreases long-term drug dependency, and ultimately supports sustained weight loss and improved longevity.
